In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive FDA 510(k) clearance, secure new funds, complete a first-in-human clinical study, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Acorai
Secured a $4.5M investment from the European Innovation Council (EIC) Fund, Taiwan Medical University, and private investors. The funds will support the company’s clinical and regulatory efforts for its non-invasive heart failure medical technology conference.
Centerline Biomedical
Received FDA 510(k) clearance for its Intra-Operative Positioning System (IOPS) Guidewire Handle following the launch of its next-generation Viewpoint catheter and sixth software release with medtech intelligence. The company also launched the latest advancements to its IOPS software platform.
Distalmotion
Successfully performed the first U.S. cases with its surgical robot, Dexter, designed to improve the accessibility of robotic surgery. This milestone comes less than 30 days after being granted FDA De Novo marketing authorization for adult inguinal hernia repair.
Freyja Healthcare
Appointed LSI Alumni Kurt Azarbarzin, former CEO of Endoquest Robotics and Verb Surgical and Founder of SurgiQuest, to its Board of Directors. The company’s mission is to improve the standard of women’s health in surgical and in-office procedures to enable physicians to provide safe, effective care.
Lauxera Capital Partners
Announced the first closing of Lauxera Growth II at €300M, representing 75% of its funding target and exceeding the size of its initial fund. Lauxera Capital Partners is an independent, global asset management firm focused on growth equity investments in commercial-stage medical devices, digital health, life sciences tools, and healthcare data.